PHAT - Phathom Pharmaceuticals

-

$undefined

N/A

(N/A)

Phathom Pharmaceuticals NASDAQ:PHAT Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.

Location: | Website: www.phathompharma.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

662.3M

Cash

334.7M

Avg Qtr Burn

-61.78M

Short % of Float

26.82%

Insider Ownership

7.73%

Institutional Own.

-

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VOQUEZNA (Vonoprazan)(Potassium competitive acid blocker) Details
Intestinal infection, Gastroesophageal reflux disease, Esophagitis

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Initiation

Phase 2

Initiation